肺动脉高压代谢组学:从病理机制到治疗靶点

Metabolomics of pulmonary hypertension:from pathological mechanisms to therapeutic targets

肺动脉高压(pulmonary hypertension,PH)是一种以肺血管重构为主要病理特征的恶性心血管病。患者通常存在显著代谢异常,包括能量代谢紊乱、脂质代谢改变和氨基酸代谢失衡。这些代谢异常与肺血管重塑、内皮功能障碍和右心室肥厚等病理生理过程密切相关。近年来,肺动脉高压代谢组学进展迅速,从早期发现代谢差异产物到目前挖掘潜在治疗靶点,代谢组学在肺动脉高压疾病中的应用加深了人们对PH发病机制的理解,加速了潜在治疗靶点的发现与筛选,部分成果已经转化到临床,有助于肺动脉高压的诊断、治疗和预后评估。

Pulmonary hypertension(PH)is a severe cardiovascular disease characterized primarily by pulmonary vascular remodeling.Patients with PH typically exhibit significant metabolic abnormalities including disruptions in energy metabolism,alterations in lipid and amino acids metabolism.These metabolic disturbances are closely linked to pathophysiological processes such as pulmonary vascular remodeling,endothelial dysfunction and right ventricular hypertrophy.In recent years,there has been rapid progress in the field of metabolomics related to PH.From the early identification of differential metabolic products to the current exploration of potential therapeutic targets,metabolomics has deepened the understanding of the pathogenesis of PH.These researches have accelerated the discovery and screening of potential therapeutic targets,with some findings already translated into clinical practice to support diagnosis,treatment and prognostic evaluation of PH.